No­var­tis to pay near­ly $178M in law­suit over BRAF drug — and will be on the hook for roy­al­ty

Af­ter a four-year bat­tle over a can­cer drug patent, No­var­tis has been or­dered by a Cal­i­for­nia judge to pay a Dai­ichi Sankyo sub­sidiary $177.8 mil­lion.

Plexxikon filed a law­suit against the phar­ma gi­ant in 2017, alledg­ing that Tafin­lar, a ri­val to its melanoma drug Zelb­o­raf that was brought to mar­ket in col­lab­o­ra­tion with Roche, has stepped on its in­tel­lec­tu­al prop­er­ty. The ju­ry ruled in its fa­vor, adding that the in­fringe­ment is in fact will­ful.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.